Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 28882536

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2017 Oct
First author
Seddon B

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Oct;18(10):1297-1299. doi: 10.1016/S1470-2045(17)30672-1.
    note
    Source null
    related pmid
    28882535
    relationship
    Comment in

Authors and identifiers

  1. name
    Seddon B
    type
    Author
  2. name
    Strauss SJ
    type
    Author
  3. name
    Whelan J
    type
    Author
  4. name
    Leahy M
    type
    Author
  5. name
    Woll PJ
    type
    Author
  6. name
    Cowie F
    type
    Author
  7. name
    Rothermundt C
    type
    Author
  8. name
    Wood Z
    type
    Author
  9. name
    Benson C
    type
    Author
  10. name
    Ali N
    type
    Author
  11. name
    Marples M
    type
    Author
  12. name
    Veal GJ
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Seddon B
    type
    Author
  2. name
    Strauss SJ
    type
    Author
  3. name
    Whelan J
    type
    Author
  4. name
    Leahy M
    type
    Author
  5. name
    Woll PJ
    type
    Author
  6. name
    Cowie F
    type
    Author
  7. name
    Rothermundt C
    type
    Author
  8. name
    Wood Z
    type
    Author
  9. name
    Benson C
    type
    Author
  10. name
    Ali N
    type
    Author
  11. name
    Marples M
    type
    Author
  12. name
    Veal GJ
    type
    Author
bibliography ids
  1. nci-bib-94696a98f5d97ee0590ee0eb
book metadata
content sha256
cb5ca4a3dd0f785a83f80e0de069a8780d2a2d1c4d405f76f9a2669ed82f409d
document type
citation
dois
  1. 10.1016/S1470-2045(17)30622-8
electronic publication date
display
2017 Sep 4
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:28882536
immutable id
pubmed:28882536@cb5ca4a3dd0f785a83f80e0de069a8780d2a2d1c4d405f76f9a2669ed82f409d
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
10
name
The Lancet. Oncology
nlm unique id
100957246
pages
1397-1410
volume
18
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Oct;18(10):1297-1299. doi: 10.1016/S1470-2045(17)30672-1.
    note
    Source null
    related pmid
    28882535
    relationship
    Comment in
outcomes validated
false
pmid
28882536
provenance
batch id
fb25b16edcb1373b70c1
provider
NCBI PubMed ESummary
record sha256
6020b6ab8ea6279f33e4c04cd6b56894e0071af61486e5bf5b099c5e0c11f311
response sha256
182c99bf1974b58308315b66aa28d31c61e8fc31cf3de4cadb0340a4f6734c52
retrieved at
2026-09-09T23:47:28.490065+00:00
publication date
display
2017 Oct
precision
month
year
2017
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/28882536/
title
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.

Preserved source evidence · Not medical advice